Author Archives: Press Release
BD Completes Acquisition of Critical Care from Edwards Lifesciences
BD announced it has completed the acquisition of Edwards Lifesciences’ Critical Care product group, which will be renamed as BD Advanced Patient Monitoring.
Owlet Announces Expanded Availability of Medically-Certified Dream SockTM Across Europe
Owlet debuts new Dream Sock at Kind + Jugend 2024 and shares that the device will soon be available to even more parents across the globe.
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment of symptomatic CCM in subsequent studies.
FIRST ALL-FEMALE TAVI TRIAL SHOWS EXCELLENT OUTCOMES FOR WOMEN RECEIVING EDWARDS VALVES
Edwards Lifesciences announced the results from the RHEIA Trial.
Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal.
FDA Clears Balloon Dilation Scoring and Constraining Platform to Treat Small or Distal Peripheral Vasculature
Transformative Angioplasty Sheath Platform Compatible with a Broad Range of Off-the-Shelf PTA and PTCA Angioplasty Balloons Cleared by FDA
Renew Biotechnologies
Renew Biotechnologies is a dynamic holding company dedicated to acquiring, developing, and commercializing impactful biotechnology.
BioUtah Organizes Stryker, bioMérieux Tours for State Legislators
State legislators got a first hand look at Utah’s life sciences industry.
New FDA Cleared Balloon Catheter Used for Vessel Occlusion During Patient Resuscitation
Temporary vessel occlusion a growing practice for trauma patients.
SINTX TECHNOLOGIES TO EXPLORE STRATEGIC OPPORTUNITIES
SINTX Technologies announced that its Board of Directors has initiated a process to explore potential strategic options for the Company.
PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care
Groundbreaking at-home pivotal trial of a much-anticipated therapeutic device is underway
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
